Cell and gene therapies are set to transform treatment of high-prevalence retinal disease. But while the pipeline is accelerating, delivery capacity is not. Existing techniques cannot scale to meet projected demand – and incremental improvements will not close the gap.
This e-book sets out, in practical terms, what that means for engineering and R&D leaders shaping the next wave of ocular therapies.
You’ll discover:
- Why retinal pipelines are shifting toward cell and gene therapies, and what that means for delivery
- The anatomical barriers that limit current ocular delivery routes for advanced therapies
- Why eye drops and intravitreal injections won’t scale for next-generation retinal treatments
- The procedural and capacity constraints holding back sub-retinal delivery today
- What radically improved delivery tools must achieve to enable safe, scalable retinal therapy
There is time to think big, but there is not time to wait.
.avif)
